Diabetic Retinopathy

Detailed Overview

Chronic hyperglycemia induces biochemical abnormalities including the activation of the polyol pathway, increased advanced glycation end-products (AGEs), and protein kinase C activation. These lead to the loss of pericytes and endothelial cell death, causing blood-retinal barrier breakdown and capillary nonperfusion. Progressive retinal ischemia stimulates the overexpression of vascular endothelial growth factor (VEGF). High VEGF levels drive pathological neovascularization, characteristic of the proliferative stage, which can bleed into the vitreous or cause tractional retinal detachment.

Epidemiology & Demographics

Prevalence is approximately 34.6% among all adults with diabetes. The incidence increases with the duration of diabetes; after 20 years, over 60% of type 2 and nearly 99% of type 1 diabetics develop some degree of retinopathy.

Etiological Mechanism

The primary etiology is sustained systemic hyperglycemia. Additional contributing factors include coexisting systemic hypertension and dyslipidemia, which further exacerbate microvascular endothelial damage.

Primary Causes

Type 1 Diabetes Mellitus

Type 2 Diabetes Mellitus

• Duration of Diabetes: The strongest risk factor; risk increases substantially after 10-15 years of disease.
• Poor Glycemic Control: Higher HbA1c levels directly correlate with incidence and progression.
• Hypertension: Elevated blood pressure exacerbates shear stress on retinal capillaries.
• Diabetic Nephropathy: Strongly associated; indicates widespread microvascular disease.

Chronic hyperglycemia leads to the accumulation of sorbitol and AGEs, causing selective apoptosis of retinal intramural pericytes. This weakens capillary walls, forming microaneurysms (the earliest clinical sign). Endothelial dysfunction leads to increased vascular permeability, allowing lipid and fluid leakage into the macula (diabetic macular edema). Subsequent capillary occlusion causes retinal ischemia. Hypoxia-inducible factor-1 (HIF-1) upregulates VEGF and angiopoietin-2, promoting the growth of fragile, abnormal new blood vessels on the retinal surface and optic disc (proliferative diabetic retinopathy).

Characteristic Clinical Presentation

• Asymptomatic: Early stages typically present with no visual changes.
• Blurred Vision: Fluctuating visual acuity, often due to macular edema or changing refractive index of the lens.
• Floaters: Sudden onset of dark spots or cobwebs in the visual field, indicating vitreous hemorrhage.
• Scotoma: Patchy areas of vision loss or a shadow across the visual field.

Physical Examination Signs

• Microaneurysms (Dot hemorrhages)
• Hard exudates (Lipid deposits)
• Cotton-wool spots (Nerve fiber layer infarctions)
• Intraretinal microvascular abnormalities (IRMA)
• Neovascularization of the disc (NVD) or elsewhere (NVE)

• Diabetic Macular Edema (DME): Retinal thickening from leaky blood vessels, the most common cause of vision loss.
• Vitreous Hemorrhage: Bleeding from neovascular vessels into the vitreous cavity.
• Tractional Retinal Detachment: Fibrovascular bands contract and pull the retina away from the underlying RPE.
• Neovascular Glaucoma: New vessels grow into the anterior chamber angle, blocking aqueous outflow.

Diagnostic Criteria & Guidelines

Diagnosis is based on dilated fundus examination revealing characteristic signs (e.g., microaneurysms, hard exudates, neovascularization). Optical Coherence Tomography (OCT) is required to quantify central subfield thickness for DME (e.g., >320 µm in men, >305 µm in women). Fluorescein Angiography shows leakage from microaneurysms, capillary non-perfusion, and hyperfluorescence of neovascularization.

Differential Diagnosis

• Hypertensive Retinopathy
• Retinal Vein Occlusion
• Ocular Ischemic Syndrome
• Radiation Retinopathy

Laboratory Tests & Biomarkers

• Hemoglobin A1c (HbA1c): Elevated (typically >7.0%)
• Fasting Lipid Panel: Often abnormal (e.g., LDL >100 mg/dL, Triglycerides >150 mg/dL)
• Urine Microalbumin/Creatinine Ratio: Often elevated (>30 mg/g) indicating concurrent nephropathy

Imaging Modalities & Findings

• Fundus Photography:
• Optical Coherence Tomography (OCT):
• Fluorescein Angiography (FA):

• Mild NPDR
  Presence of at least one microaneurysm but no other lesions.
• Moderate NPDR
  Hemorrhages/microaneurysms, hard exudates, cotton wool spots, but less than severe NPDR.
• Severe NPDR
  4-2-1 rule: Severe hemorrhages in 4 quadrants, venous beading in 2+ quadrants, or IRMA in 1+ quadrant.
• PDR
  Proliferative diabetic retinopathy with neovascularization, vitreous/preretinal hemorrhage.

Second-Line & Adjunctive Therapy

For persistent DME failing anti-VEGF: Intravitreal corticosteroids (e.g., Dexamethasone 0.7 mg intravitreal implant every 4-6 months, or Fluocinolone acetonide 0.19 mg implant). Warning: high risk of cataracts and IOP elevation.

Surgical & Procedural Management

Pars Plana Vitrectomy (PPV). Indications include: non-clearing vitreous hemorrhage (>1-3 months), tractional retinal detachment involving or threatening the macula, and combined tractional/rhegmatogenous retinal detachment.

Recommended Lifestyle Changes

• Strict adherence to a diabetic diet to maintain euglycemia.
• Moderate aerobic exercise (150 minutes/week) if cleared, but avoid heavy lifting or Valsalva maneuvers if PDR is present to prevent hemorrhage.
• Smoking cessation to reduce cardiovascular and microvascular damage.

Patient Counseling & Advice

Emphasize that early stages are asymptomatic and vision loss is often preventable if caught early. Instruct that controlling blood sugar, blood pressure, and cholesterol is as important as eye treatments. Warn against sudden strenuous activities if diagnosed with PDR.

Follow-Up & Monitoring Schedule

Type 1 diabetes: Initial exam 5 years after diagnosis, then annually. Type 2 diabetes: Initial exam at time of diagnosis, then annually. Women with preexisting diabetes who become pregnant should be examined in the 1st trimester and monitored closely throughout pregnancy. Patients with established retinopathy need follow-up every 1-6 months depending on severity.

Preventive Strategies

Primary prevention involves strict glycemic and blood pressure control. The DCCT trial demonstrated that intensive glycemic control reduces the risk of developing retinopathy by 76%.

With timely laser or anti-VEGF therapy, the risk of severe vision loss is reduced by over 90%. However, without treatment, severe PDR has a >50% rate of severe vision loss within 5 years.